Delivery of micro-dystrophin using adeno-associated viral (AAV) vector to express a functional, though shorter dystrophin protein, called micro-dystrophin, with preserved N- and C-termini in muscles is also an FDA-approved treatment for DMD, called ELEVIDYS. This evidence concerns the gene DMD and Duchenne muscular dystrophy.